Technology helps Indians choose baby's sex
By Australian Broadcasting Company,
Australian Broadcasting Company
| 11. 12. 2004
New reproductive technologies are tipping the sex balance of babies born in India further in favour of boys, an international conference has heard.
This is despite efforts to stem the growing use of technologies like pre-implantation diagnosis that have already weeded out millions of girls from the birth statistics.
And the proportion of girls may drop even further with plans to stabilise India's population over the next 10 to 15 years, say some observers.
The World Bioethics Congress in Sydney this week heard that despite laws limiting the use of prenatal and preconception technologies to diagnosing disease, such technologies were still being used to favour baby boys.
And at last count the ratio of girls to boys was still falling.
Dr Vasantha Muthuswamy, senior deputy director general of the Indian Council of Medical Research in New Delhi, said the 2001 census reported there were 927 girls for every 1000 boys. This compares with 976 girls for every 1000 boys in 1961.
She said this was a long-term problem. But in the past 20 years there had been a sharp decline...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...